Page last updated: 2024-11-06

iopamidol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Iopamidol is a nonionic, water-soluble contrast agent used in various medical imaging techniques, including computed tomography (CT) and angiography. It is synthesized through a multi-step process involving the reaction of a specific amine with a derivative of glutaric anhydride. The iodine atoms in iopamidol are responsible for its radiopaque properties, allowing for better visualization of organs and structures during imaging. Iopamidol is known to have a relatively low incidence of adverse effects, but it can cause allergic reactions in some individuals. It is studied extensively to improve its safety and efficacy, explore new applications, and investigate its potential impact on various biological systems.'

Iopamidol: A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

iopamidol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65492
CHEMBL ID1200932
CHEBI ID31711
SCHEMBL ID27781
SCHEMBL ID23804118
MeSH IDM0011680

Synonyms (145)

Synonym
sq-13396
niopam
iopamiron
iopamiro
gastromiro
iopamyron
BSPBIO_000941
n,n'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-{[(2s)-2-hydroxypropanoyl]amino}-2,4,6-triiodobenzene-1,3-dicarboxamide
BPBIO1_001037
iopamiron 300
b 15000
isovue 370
iopamiron 370
b-15000
1,3-benzenedicarboxamide, n,n'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-((2-hydroxy-1-oxopropyl)amino)-2,4,6-triiodo-, (s)-
(s)-n,n'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-2,4,6-triiodo-5-lactamidoisophthalamide
l-5alpha-idrossipropionilamino-2,4,6-triiodoisoftal-di(1,3-diidrossi-2-propilamide)
l-5alpha-hydroxypropionylamino-2,4,6-triiodoisophthalic acid di(1,3-dihydroxy-2-propylamide)
jopamiron 200
l-(+)-n,n'-bis(2-hydroxy-1-hydroxymethylethyl)-2,4,6-triiodo-5-lactamide isophthalamide
iopamiro 370
iopamidol 300
oypalomin
solutrast 370
sq 13396
1,3-benzenedicarboxamide, n,n'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-(((2s)-2-hydroxy-1-oxopropyl)amino)-2,4,6-triiodo-
(s)-n,n'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-((2-hydroxy-1-oxopropyl)amino)-2,4,6-triiodoisophthaldiamide
brn 6250226
solutrast
einecs 262-093-6
isovue-370
iopamidolum [inn-latin]
niopam 300
cas-60166-93-0
NCGC00016892-01
iopamidol
isovue
PRESTWICK2_000871
PRESTWICK3_000871
AB00513941
D01797
60166-93-0
iopamidol (jp17/usp)
isovue (tn)
iopamiron (tn)
SPBIO_002862
PRESTWICK0_000871
PRESTWICK1_000871
NCGC00016892-02
1-n,3-n-bis(1,3-dihydroxypropan-2-yl)-5-[[(2s)-2-hydroxypropanoyl]amino]-2,4,6-triiodobenzene-1,3-dicarboxamide
sq 13,396
CHEMBL1200932
62883-00-5
n,n'-bis(1,3-dihydroxypropan-2-yl)-5-{[(2s)-2-hydroxypropanoyl]amino}-2,4,6-triiodobenzene-1,3-dicarboxamide
CHEBI:31711 ,
iopamidolum
HMS1570P03
A834067
n1,n3-bis(1,3-dihydroxypropan-2-yl)-5-(2-hydroxypropanoylamino)-2,4,6-triiodo-benzene-1,3-dicarboxamide
HMS2097P03
jopamidol
1,3-benzenedicarboxamide, n,n'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-((2-hydroxy-1-oxopropyl)amino)-2,4,6-triiodo-
iomapidol
pharmakon1600-01502304
nsc759636
dtxcid203158
dtxsid1023158 ,
tox21_110668
S4532
iopamidol-300 in plastic container
iopamidol-200 in plastic container
unii-jr13w81h44
isovue-250
iopamidol-250
scanlux-370
iopamidol-300
isovue-128
iopamidol-250 in plastic container
scanlux-300
isovue-m 300
iopamidol-200
iopamidol-370
isovue-200
iopamidol-370 in plastic container
hsdb 8075
isovue-300
jr13w81h44 ,
iopamidol [usan:usp:inn:ban:jan]
isovue-m 200
iopamidol [jan]
iopamidol [vandf]
iopamidol [mi]
iopamidol [ep impurity]
iopamidol [mart.]
iopamidol [orange book]
iopamidol [ep monograph]
iopamidol [usp monograph]
iopamidol [who-dd]
iopamidol [inn]
iopamidol [usan]
AKOS015891034
BRD-K75868704-001-01-2
CCG-213024
HY-B0684
(s)-n,n'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide
XQZXYNRDCRIARQ-LURJTMIESA-N
SCHEMBL27781
tox21_110668_1
NCGC00016892-04
Q-201245
KS-1421
AB00513941_02
DB08947
n1,n3-bis(1,3-dihydroxypropan-2-yl)-5-[(2s)-2-hydroxypropanamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
iopamidol; n,n'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[[(2s)-2-hydroxypropanoyl]amino]-2,4,6-triiodobenzene-1,3-dicarboxamide
HMS3714P03
Q424788
(s)-n1,n3-bis(1,3-dihydroxypropan-2-yl)-5-(2-hydroxypropanamido)-2,4,6-triiodoisophthalamide
(s)-n1,n3-bis(1,3-dihydroxypropan-2-yl)-5-(2-
hydroxypropanamido)-2,4,6-triiodoisophthalamide
(s)-n,n inverted exclamation marka-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodo-5-lactamidoisophthalamide
b-15000;sq-13396
H11976
n,n'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[[(2s)-2-hydroxy-1-oxopropyl]amino]-2,4,6-triiodo-1,3-benzenedicarboxamide
EN300-19767815
SCHEMBL23804118
isovue300
isovue-m
iopamidol (usan:usp:inn:ban:jan)
n,n'bis
l-(+)-n,n'-bis(2-hydroxy-1-hydroxymethylethyl)-2,4,6-triiodo-5- lactamide isophthalamide
isovue200
v08ab04
iopamidol (ep impurity)
isovue370
iopamidolum (inn-latin)
iopamidol (ep monograph)
n,n'-bis(1,3-dihydroxypropan-2-yl)-5-(((2s)-2-hydroxypropanoyl)amino)-2,4,6-triiodobenzene-1,3-dicarboxamide
iopamidolo
n,n'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-((2s)-2-hydroxypropanoylamino)-2,4,6-triiodoisophthalamide
(s)-n,n'-bis
iopamidol (mart.)
iopamidol (usp monograph)
isovue250
mfcd00867931

Research Excerpts

Overview

Iopamidol is a commonly used iodinated X-ray contrast media in medical field. Its residue in water can react with disinfectants to form highly toxic iodinated disinfection by-products (I-DBPs). It is a known direct precursor to iodinated and chlorinated DBP formation.

ExcerptReferenceRelevance
"Iopamidol is a nonionic, low-osmolar iodinated contrast agent used for angiography. "( Nephrotoxicity of iopamidol is associated with mitochondrial impairment in human cell and teleost models.
Bolten, JS; Fricker, G; Huwyler, J; Kraus, L; Mancuso, RV; Mayr, A; Odermatt, A; Puligilla, RD; Roos, NJ, 2023
)
2.69
"Iopamidol is a radiographic contrast media which caused a very high incidence of anaphylactic reactions. "( A mast-cell-specific receptor mediates Iopamidol induced immediate IgE-independent anaphylactoid reactions.
An, H; Che, D; Hu, S; Jiang, W; Liu, R, 2019
)
2.23
"Iopamidol is a commonly used iodinated X-ray contrast media in medical field, and its residue in water can react with disinfectants to form highly toxic iodinated disinfection by-products (I-DBPs). "( Iodinated trihalomethanes formation in iopamidol-contained water during ferrate/chlor(am)ination treatment.
Dong, ZY; Hu, CY; Li, M; Pan, Y; Tang, YL; Wang, Z; Xian, Q; Xu, B; Yu, SL; Zhang, TY, 2021
)
2.33
"Iopamidol is a known direct precursor to iodinated and chlorinated DBP formation; however, the influence of iopamidol on both iodo/chloro-DBP formation has yet to be fully investigated. "( Formation of DBPs and halogen-specific TOX in the presence of iopamidol and chlorinated oxidants.
Ackerson, NOB; Crafton, EA; Duirk, SE; Killinger, AH; Kumkum, P; Liberatore, HK; Machek, EJ; Plewa, MJ; Richardson, SD; Ternes, TA, 2018
)
2.16
"Iopamidol is a new, nonionic, water-soluble contrast material currently undergoing clinical trials for intravascular and intrathecal use in Europe and the United States. "( Iopamidol in lumbar myelography.
Chirico-Post, J; Harris, JM; Kleefield, J; Levine, HL; Robbins, AH; Rommel, AJ; Srinivasan, MK, 1983
)
3.15
"Iopamidol was found to be a very favourable contrast medium as far as the kidneys are concerned."( [Value of iopamidol in radiologic diagnosis].
Baars, HG; Kelemen, J; Monoki, E; Pokorny, L; Szücs, A, 1984
)
1.39
"Iopamidol is a nonionic water-soluble contrast medium that may be considered in such situations."( Iopamidol as a gastrointestinal contrast agent. Lack of peritoneal reactivity.
Cheng, SC; Ferrante, SL; Frick, MP; Rouse, JW; Rysavy, JA; Schreiman, JS, 1990
)
2.44

Actions

Iopamidol induced an increase in relative refractory period in both myocardium and Purkinje fibres at 1 mL/L and had a significant effect on all parameters studied at 10 ml/L. Iopamids cause a negative susceptibility shift and T1, T2, and T2* shortening.

ExcerptReferenceRelevance
"Iopamidol and iopromide cause a negative susceptibility shift and T1, T2, and T2* shortening. "( MRI Appearance of Intracerebral Iodinated Contrast Agents: Is It Possible to Distinguish Extravasated Contrast Agent from Hemorrhage?
Abbas, Z; Dekeyzer, S; Jablawi, F; Lindemeyer, J; Nikoubashman, O; Oros-Peusquens, AM; Othman, AE; Shah, NJ; Wiesmann, M, 2016
)
1.88
"Iopamidol induced an increase in relative refractory period in both myocardium and Purkinje fibres at 1 mL/L and had a significant effect on all parameters studied at 10 mL/L."( Electrophysiological effects of contrast media.
Fillette, F; Nassif, G, 1987
)
0.99

Treatment

ExcerptReferenceRelevance
"Both iopamidol and iodixanol treatments deceased cell viability and increased apoptosis of HUVEC and H5V cells, along with downregulated NOS and ABCG1."( Hypotonic contrast media is more toxic than isotonic contrast media on endothelial cells in vivo and in vitro.
Liu, Y; Lv, S; Ren, L; Wang, P; Wang, Z, 2017
)
0.91

Toxicity

iopamidol was not toxic at concentrations up to 101 mg/L. The brush-border enzymes AAP and gamma-GT are sensitive markers for this toxicity. iomeprol 150 mgI/ml, and iopAmidol 150 mg I/ml are equally effective and well tolerated.

ExcerptReferenceRelevance
" The results of these studies demonstrate that ioversol is an effective, well tolerated and safe contrast agent for intravenous excretory urography."( Ioversol in intravenous excretory urography. Evaluation of radiographic quality, patient tolerance and safety in four clinical studies.
Jahn, H; Müller-Späth, R, 1992
)
0.28
"The low osmolar, non-ionic X-ray contrast media have shown a lower frequency of adverse events than the older ionic ones."( Safety and tolerability of iodixanol in healthy volunteers with reference to two monomeric X-ray contrast media.
Borch, KW; Jørgensen, NP; Kristiansen, AB; Kristoffersen, DT; Lundby, B; Nossen, JO; Theodorsen, L, 1992
)
0.28
" During the followup period (five days at most), we found localized urtication as a side effect in only one case (4."( Side effects and pharmacokinetics of nonionic iodinated contrast medium in hemodialyzed patients.
Harasawa, H; Masuko, K; Yamazaki, C, 1990
)
0.28
" The observed toxic effects were markedly potentiated by concomitant hypoxia."( Comparison of toxicity of radiocontrast agents to renal tubule cells in vitro.
Cieslinski, DA; Humes, HD; Messana, JM, 1990
)
0.28
" Mechanisms of severe adverse reactions are reviewed, including the views of Lasser and Lalli, and the view that emphasizes the importance of cardiotoxic and hemodynamic effects."( Chemotoxicity of contrast media and clinical adverse effects: a review.
Dawson, P,
)
0.13
" When the acute intravenous toxicity of 35% I, wt/vol, ioversol was compared with 35% I, wt/vol, iohexol and 37% I, wt/vol, iopamidol in mice, no significant differences in LD50 values or general toxicity were found."( Acute and subacute toxicity studies of ioversol in experimental animals.
Blair, M; Coveney, J; Ralston, WH; Robbins, MS, 1989
)
0.48
" Our data suggest that the nonionic low-osmolal radiocontrast medium iopamidol is less toxic to tubules than the ionic high-osmolal medium diatrizoate and that the brush-border enzymes AAP and gamma-GT are sensitive markers for this toxicity."( Tubular nephrotoxicity after intravenous urography with ionic high-osmolal and nonionic low-osmolal contrast media in patients with chronic renal insufficiency.
Arrigo, G; Bernasconi, P; Cavaliere, G; D'Amico, G; Dellafiore, L; Schiavina, G; Vergnaghi, D, 1987
)
0.51
"When cervical myelography is required, the highest incidence of adverse effects usually supervenes."( Low dose cervical CT myelography. How acceptable are adverse effects at this juncture?
Ahn, HS; Kim, WS; Kumar, AJ; Rosenbaum, AE; Updike, ML; Wang, H; Zinreich, SJ, 1986
)
0.27
" Recent experiments have demonstrated that sodium diatrizoate, a common ionic radiocontrast agent, is moderately toxic to proximal tubule cells in vitro, and that this toxicity is enhanced by hypoxia."( Comparison of the toxicity of the radiocontrast agents, iopamidol and diatrizoate, to rabbit renal proximal tubule cells in vitro.
Cieslinski, DA; Humes, HD; Messana, JM; Nguyen, VD, 1988
)
0.52
" Diatrizoate sodium meglumine was the most toxic agent, followed by diatrizoate and meglumine, iothalamate meglumine, and mannitol in terms of blood-brain barrier (BBB) disruption and coupled perfusion decline."( Comparative neurotoxicity of angiographic contrast media.
Albright, R; Drayer, B; Fram, E; Velaj, R, 1985
)
0.27
" No complications or adverse reactions occurred in either group."( Safety of contrast media in cerebral angiography: iopamidol vs. methylglucamine iothalamate.
Allen, S; Bates, M; Bird, CR; Drayer, BP; Heinz, ER; Osborne, DR; Triolo, PJ; Velaj, R; Yeates, AE,
)
0.38
"Water-soluble contrast agents (metrizamide) provide a finer myelographic assessment of the spinal neuroanatomical structures but at the expense of some occasional toxic side effects."( Double blind study of the toxicity of intrathecal iopamidol and metrizamide in lumbar myelography.
Fox, AJ; Vézina, JL, 1984
)
0.52
"Selective vertebral angiography was performed in 29 rabbits in order to compare the adverse effects of three monomeric (iopamidol, iopromide, metrizamide) and one dimeric (iodecol) non-ionic water-soluble contrast medium."( The toxicity of non-ionic water-soluble monomeric and dimeric contrast media in selective vertebral angiography. An experimental study in rabbits.
Skalpe, IO, 1983
)
0.47
"In several series of experiments with intracardiac application in anaesthetized dogs, the following contrast media were tested for their adverse effects on excitation and conduction of electrical activity in the heart."( Contrast media-induced side effects on excitation and conduction of electrical activity in the heart on intracardiac application. Investigations in anaesthetized dogs.
Diletti, E; Felix, R; Hahn, N; Logemann, N; Mählmann, J; Pantenburg, R; Potthoff, E; Raqué, B; Schmidt, I; Schuppert, J; Siering, T; Steinijans, V; Stiemert, D, 1981
)
0.26
" Out of 7799 patients to whom iomeprol was administered, adverse events were observed in only 437 (5."( Clinical utility and safety profile of iomeprol.
Rosati, G, 1994
)
0.29
" Both agents appeared to be safe and well tolerated."( Double-blind comparison of safety and efficacy of iomeprol and iopamidol in carotid digital subtraction angiography.
Beltramello, A; Piovan, E; Rosta, L, 1994
)
0.53
" The results of our study show that iomeprol 150 mgI/ml, and iopamidol 150 mgI/ml are equally effective, well tolerated and safe contrast agents when used for IA-DSA."( A double-blind comparative study of the safety and efficacy of iomeprol in renal intra-arterial digital subtraction angiography.
Canalis, GC; Carpanese, L; Guazzaroni, M; Simonetti, G; Urigo, F, 1994
)
0.53
" Adverse reactions were sought, physical examinations were performed, and standard hematology and serum chemistry values were measured before and 1 day after injection; a 72-hour serum creatinine level was also measured."( Efficacy and safety of iopromide for excretory urography.
Amis, ES; Goldman, S; Hedgcock, M; Khazan, R; Landman, J; Lang, E; Leder, R; Newhouse, JH, 1994
)
0.29
" Mild adverse reactions were experienced by 10% of patients; there were no significant differences in reaction rates among contrast agents."( Efficacy and safety of iopromide for excretory urography.
Amis, ES; Goldman, S; Hedgcock, M; Khazan, R; Landman, J; Lang, E; Leder, R; Newhouse, JH, 1994
)
0.29
"Iopromide at a dose of approximately 300 mg I/kg is safe and effective as an excretory urographic agent and is comparable in performance with ioversol and iopamidol."( Efficacy and safety of iopromide for excretory urography.
Amis, ES; Goldman, S; Hedgcock, M; Khazan, R; Landman, J; Lang, E; Leder, R; Newhouse, JH, 1994
)
0.49
" Adverse events were monitored by investigators, and efficacy was evaluated by grading the radiographic images."( Safety and efficacy of iopromide in cerebral arteriography.
Drayer, BP; Haughton, VM; Hilal, SK; Hyland, D; Maravilla, K; Osborn, AG; Papke, RA, 1994
)
0.29
"Most adverse events were mild or moderate in severity; all resolved completely."( Safety and efficacy of iopromide in cerebral arteriography.
Drayer, BP; Haughton, VM; Hilal, SK; Hyland, D; Maravilla, K; Osborn, AG; Papke, RA, 1994
)
0.29
"These study results indicate that iopromide is a safe and effective contrast medium for cerebral angiography."( Safety and efficacy of iopromide in cerebral arteriography.
Drayer, BP; Haughton, VM; Hilal, SK; Hyland, D; Maravilla, K; Osborn, AG; Papke, RA, 1994
)
0.29
" Minor adverse clinical experiences were noted in 23% of the iopromide group versus 20% of the comparator group."( Double-blind study of the safety, tolerance, and diagnostic efficacy of iopromide as compared with iopamidol and iohexol in patients requiring aortography and visceral angiography.
Athanasoulis, C; Bron, K; Cope, C; Druy, EM; Faykus, MH; Hedgcock, M; Miller, FJ, 1994
)
0.51
"Tolerance of a New Non-ionic Contrast Medium during Heart Catheterization The new non-ionic contrast medium iomeprol (CAS 78649-41-9) was investigated for adverse reactions and diagnostic quality in 75 patients undergoing heart catheterization."( [Adverse effects of a new non-ionic contrast medium in heart catheterization].
Jost, S; Lichtlen, P; Meyer, GP; Rafflenbeul, W; Trappe, HJ; Wenzlaff, P, 1993
)
0.29
"The use of the newest nonionic, water-soluble, low-osmolar radiographic contrast media (CM) is still associated with occasional adverse reactions affecting the neural tissues."( Neurotoxicity of nonionic low-osmolar contrast media. A receptor binding study.
Bernasconi, P; Fiori, MG; Mennini, T, 1993
)
0.29
" Nature,onset,intensity as well as outcome of each adverse reaction was reported."( Safety and efficacy of Xenetix, a new iodinated contrast agent, in pediatric angiocardiography.
Chantepie, A; Losay, J; Lusson, JR; Rossignol, AM, 1996
)
0.29
"Iobitridol is a safe and effective contrast agent for pediatric angiocardiography."( Safety and efficacy of Xenetix, a new iodinated contrast agent, in pediatric angiocardiography.
Chantepie, A; Losay, J; Lusson, JR; Rossignol, AM, 1996
)
0.29
" The purpose of this study was to determine the incidence of minor and major adverse reactions and postphlebographic DVT when using nonionic contrast (iopamidol)."( Prospective study of safety of lower extremity phlebography with nonionic contrast medium.
AbuRahma, AF; Powell, M; Robinson, PA, 1996
)
0.49
"Minor adverse reasons, including nausea, local pain, and dizziness, occurred in 11 (7%) of 157 patients; however, no major complications or postphlebographic DVT was found in the 102 patients who underwent postphlebography duplex ultrasound."( Prospective study of safety of lower extremity phlebography with nonionic contrast medium.
AbuRahma, AF; Powell, M; Robinson, PA, 1996
)
0.29
" Clinical safety was assessed by the reporting of adverse events and diagnostic efficacy was evaluated."( Evaluation of the clinical safety and efficacy of iobitridol (Xenetix) in intravenous urography.
Fournier, PJ; Freitag, P; Steinbrich, W; Voegeli, E, 1996
)
0.29
"The radiocontrast agents reduced cell viability to a greater extent than hyperosmolal mannitol solutions in both cell lines; diatrizoate was more toxic than iopamidol."( Cytotoxicity of radiocontrast agents on polarized renal epithelial cell monolayers.
Haller, C; Kübler, W; Schick, CS; Zorn, M, 1997
)
0.49
"Diatrizoate is more toxic than iopamidol, which is partly related to its higher osmolality."( Cytotoxicity of radiocontrast agents on polarized renal epithelial cell monolayers.
Haller, C; Kübler, W; Schick, CS; Zorn, M, 1997
)
0.58
" With modern contrast media and technique, pulmonary angiography is a safe procedure."( Pulmonary angiography: a safe procedure with modern contrast media and technique.
Carlsson, A; Mâre, K; Nilsson, T, 1998
)
0.3
" The safety controls performed consisted of preand postdose complete physical examinations, measurement of vital signs, electrocardiographic controls, clinical laboratory investigations (hematology, serum chemistry, and urinalysis), and monitoring of adverse events."( Safety and pharmacokinetics of a new liposomal liver-specific contrast agent for CT: results of clinical testing in nonpatient volunteers.
Alvino, S; Ceriati, S; Fouillet, X; Lorusso, V; Luzzani, F; Pianezzola, P; Rummeny, EJ; Spinazzi, A, 2000
)
0.31
"No serious adverse events occurred throughout the study."( Safety and pharmacokinetics of a new liposomal liver-specific contrast agent for CT: results of clinical testing in nonpatient volunteers.
Alvino, S; Ceriati, S; Fouillet, X; Lorusso, V; Luzzani, F; Pianezzola, P; Rummeny, EJ; Spinazzi, A, 2000
)
0.31
"BR21 appeared to be safe and well tolerated in nonpatient subjects."( Safety and pharmacokinetics of a new liposomal liver-specific contrast agent for CT: results of clinical testing in nonpatient volunteers.
Alvino, S; Ceriati, S; Fouillet, X; Lorusso, V; Luzzani, F; Pianezzola, P; Rummeny, EJ; Spinazzi, A, 2000
)
0.31
"This study was designed to determine whether a mixture of iodinated contrast material and gadopentetate dimeglumine used during MR arthrography yields free gadolinium ion, a systemically toxic metal."( Is a mixture of gadolinium and iodinated contrast material safe during MR arthrography?
Brown, RR; Clarke, DW; Daffner, RH, 2000
)
0.31
"Gadopentetate dimeglumine and iodinated contrast material can be mixed before MR imaging without any release of free gadolinium and are therefore safe for confirming the intraarticular placement of contrast material before MR arthrography."( Is a mixture of gadolinium and iodinated contrast material safe during MR arthrography?
Brown, RR; Clarke, DW; Daffner, RH, 2000
)
0.31
" No adverse effects on blood pressure, pulse, arterial oxygen saturation, end-tidal CO2, or intracranial pressure were noted with the use of CO2."( Safety and accuracy of bedside carbon dioxide cavography for insertion of inferior vena cava filters in the intensive care unit.
Heniford, BT; Jacobs, DG; Sing, RF; Stackhouse, DJ, 2001
)
0.31
"Carbon dioxide as a contrast agent is safe and provides accurate determination of vena caval diameter and anatomy."( Safety and accuracy of bedside carbon dioxide cavography for insertion of inferior vena cava filters in the intensive care unit.
Heniford, BT; Jacobs, DG; Sing, RF; Stackhouse, DJ, 2001
)
0.31
" Safety was determined by predose and postdose (up to 10 days) measurement of vital signs, hematology, blood chemistry, urinalysis, electrocardiogram, physical examinations, and the incidence of adverse events."( Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis.
Alvino, S; Lorusso, V; Spinazzi, A; Taroni, P, 2001
)
0.31
" Mild to moderate adverse events were reported by 17 of 30 subjects; none was clinically meaningful."( Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis.
Alvino, S; Lorusso, V; Spinazzi, A; Taroni, P, 2001
)
0.31
" In this risk population, iomeprol 400 was safe and well tolerated."( Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis.
Alvino, S; Lorusso, V; Spinazzi, A; Taroni, P, 2001
)
0.31
" No difference was found between the groups regarding the frequency of patients having adverse reactions (5."( Pain in femoral arteriography. A double-blind, randomized, clinical study comparing safety and efficacy of the iso-osmolar iodixanol 270 mgI/ml and the low-osmolar iomeprol 300 mgI/ml in 9 European centers.
Batakis, O; Fog, A; Manke, C; Marcus, C; Page, A; Puey, J, 2003
)
0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" From the FDA databases, we evaluated 18 adverse event terms associated with renal injury or dysfunction after CM use."( Contrast media and nephropathy: findings from systematic analysis and Food and Drug Administration reports of adverse effects.
Dumouchel, W; Solomon, R, 2006
)
0.33
"To test in vitro whether gadolinium-based contrast agents induce fewer toxic effects on renal tubular cells than does an iodinated contrast medium at concentrations used for angiography."( Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study.
Grgic, A; Heckmann, MB; Heinrich, MC; Kohlbacher, S; Kuhlmann, MK; Scheer, M; Uder, M, 2007
)
0.34
" Our results demonstrate that B-RTO is an efficacious and safe treatment for children with isolated GFV."( Efficacy and safety of balloon-occluded retrograde transvenous obliteration for gastric fundal varices in children.
Hisamatsu, C; Kawasaki, R; Maeda, K; Yasufuku, M, 2008
)
0.35
" Adverse events occurred in 1/91 (1."( Enhancement and safety of iomeprol-400 and iodixanol-320 in patients undergoing abdominal multidetector CT.
Bonomo, L; Catalano, C; Chen, KM; Dore, R; Grazioli, L; Romano, L; Vanzulli, A; Xu, JR, 2009
)
0.35
" This procedure is safe and effective and we recommend this as the first treatment for MO in ELBW infants."( Iopamidol enema treatment for meconium obstruction of prematurity in extremely low-birth weight infants: a safe and effective method.
Funato, M; Nakaoka, T; Nishihara, M; Shiokawa, C; Tamai, H; Uemura, S, 2009
)
1.8
"This procedure is safe and effective."( Iopamidol enema treatment for meconium obstruction of prematurity in extremely low-birth weight infants: a safe and effective method.
Funato, M; Nakaoka, T; Nishihara, M; Shiokawa, C; Tamai, H; Uemura, S, 2009
)
1.8
"The relationship of contrast-induced nephropathy (CIN) to long-term adverse events (AEs) is controversial."( Contrast-induced nephropathy and long-term adverse events: cause and effect?
Barrett, BJ; Doucet, S; Gelormini, JL; Katholi, RE; Labinaz, M; Mehran, R; Natarajan, MK; Sharma, SK; Solomon, RJ; Staniloae, CS, 2009
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"The purpose of the study is to examine the incidence of adverse reactions caused by non-ionic contrast media in selected patients after desensitization treatment and to evaluate the safety profile of organ iodine contrast media (i."( Safety profile and protocol prevention of adverse reactions to uroangiographic contrast media in diagnostic imaging.
Brunese, L; D'Amora, M; D'Andrea, A; Di Grezia, G; Grassi, R; Mandato, Y; Reginelli, A; Rossi, C; Rotondi, A,
)
0.13
" DEBDOX/M1 TACE was well tolerated, and the grade 3/4 adverse event rate was low (1 of 65 procedures)."( Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads: clinical-radiological outcomes and safety profile.
Bhoori, S; Cascella, T; Civelli, EM; Facciorusso, A; Marchianò, A; Mazzaferro, V; Morosi, C; Pellegrinelli, A; Rodolfo, L; Sposito, C; Spreafico, C; Vaiani, M, 2015
)
0.42
" However, little is documented about the effects of contrast on hemodynamics in heart failure patients or the prognostic value of baseline and changes in hemodynamics for predicting subsequent adverse events."( Baseline Hemodynamics and Response to Contrast Media During Diagnostic Cardiac Catheterization Predict Adverse Events in Heart Failure Patients.
Denardo, SJ; O'Connor, CM; Schmalfuss, CM; Tcheng, JE; Vock, DM; Young, GD, 2016
)
0.43
" One-year Kaplan-Meier estimates of adverse event-free survival (death, heart failure hospitalization, and rehospitalization) were generated, grouping patients by baseline measures of pulmonary capillary wedge pressure (PCWP) and cardiac index (CI), and by changes in those measures after contrast administration."( Baseline Hemodynamics and Response to Contrast Media During Diagnostic Cardiac Catheterization Predict Adverse Events in Heart Failure Patients.
Denardo, SJ; O'Connor, CM; Schmalfuss, CM; Tcheng, JE; Vock, DM; Young, GD, 2016
)
0.43
" Calculating baseline PCWP with change in CI after contrast predicts adverse events and increases the predictive value of existing models."( Baseline Hemodynamics and Response to Contrast Media During Diagnostic Cardiac Catheterization Predict Adverse Events in Heart Failure Patients.
Denardo, SJ; O'Connor, CM; Schmalfuss, CM; Tcheng, JE; Vock, DM; Young, GD, 2016
)
0.43
" Iopamidol was not toxic at concentrations up to 101 mg/L."( The effects of pharmaceuticals on a unionid mussel (Lampsilis siliquoidea): An examination of acute and chronic endpoints of toxicity across life stages.
Bendo, NA; de Solla, SR; Giacomin, M; Gillis, PL; Gilroy, ÈAM; King, LE; Salerno, J, 2017
)
1.37
" Treatment-emergent adverse events were similar between groups (iodixanol 18."( Randomized, Double-Blind Study Comparing Patient Comfort and Safety Between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Peripheral Arteriography - The COMFORT II Trial.
Lim, L; Lonjedo Vicent, E; Macho, J; Martínez-Rodrigo, JJ; Rosenberg, C; Todoran, TM, 2017
)
0.67
"The presence of iodinated X-ray contrast media (ICM) in source waters is of high concern to public health because of their potential to generate highly toxic disinfection by-products (DBPs)."( The impact of iodinated X-ray contrast agents on formation and toxicity of disinfection by-products in drinking water.
Duirk, SE; Jeong, CH; Machek, EJ; Plewa, MJ; Richardson, SD; Shakeri, M; Ternes, TA; Wagner, ED, 2017
)
0.46
" Since iopamidol was significantly more toxic than iohexol in human MSCs, a more careful examination of safety of radiocontrast dyes for clinical use is warranted."( Cytotoxicity of radiocontrast dyes in human umbilical cord mesenchymal stem cells.
Bakshi, S; Beeravolu, N; McKee, C; Perez-Cruet, M; Rasul Chaudhry, G; Thibodeau, B; Wilson, G, 2018
)
0.94
" The secondary endpoints were the mean peak SCr increase within 72 h after receiving CM and major adverse renal events (SCr increased by two times after 30 days, the need for dialysis treatment, rehospitalization for acute renal failure, or kidney-related death) during hospitalization and within 30 day postdischarge."( Nephrotoxicity of iodixanol versus iopamidol in patients undergoing peripheral angiography with or without endovascular therapy.
Che, WQ; Chen, Y; Dong, H; Gao, RL; Jiang, XJ; Peng, M; Xiong, HL; Xu, B; Yang, YJ; Zou, YB, 2018
)
0.76
"609] with doubling of SCr; no other adverse renal events were observed."( Nephrotoxicity of iodixanol versus iopamidol in patients undergoing peripheral angiography with or without endovascular therapy.
Che, WQ; Chen, Y; Dong, H; Gao, RL; Jiang, XJ; Peng, M; Xiong, HL; Xu, B; Yang, YJ; Zou, YB, 2018
)
0.76
" Intravenous provocation with a skin test-negative RCM is safe and enables identification of a tolerated alternative RCM."( Radiocontrast Media Hypersensitivity: Skin Testing Differentiates Allergy From Nonallergic Reactions and Identifies a Safe Alternative as Proven by Intravenous Provocation.
Behle, V; Brockow, K; Stoevesandt, J; Trautmann, A,
)
0.13
"The injection of contrast agent using standard peripheral venous cannulas is a safe and reliable procedure yielding diagnostic image contrast, even when using highly viscous contrast agents such as iomeprol 400; an aspiration test should be performed before each injection."( Prospective safety evaluation of automated iomeprol 400 injections for CT through peripheral venous cannulas.
Buecker, A; Fries, P; Jagoda, P; Raczeck, P; Stroeder, J, 2020
)
0.56
" In conclusion, using a dorsal approach, CT-guided cervical nerve root infiltrations with an extraforaminal needle position seem to be a safe intervention."( Safety of CT-guided cervical nerve root infiltrations using a dorsal approach.
Gossner, J, 2020
)
0.56
" NLI231 is a feasible and safe liquid embolic material for balloon-assisted embolization of wide-necked aneurysms in swine."( Feasibility and Safety of n-Butyl Cyanoacrylate-Lipiodol-Iopamidol as an Alternative Liquid Embolic Material.
Fukuda, K; Higashino, N; Ikoma, A; Kawai, N; Okuhira, R; Sonomura, T; Ueda, S, 2021
)
0.87
"5% dextrose dialysis solution is chemically stable, meeting the criteria set forth in the standards and guidelines of the US Pharmacopeia and the Institute of Safe Medication Practices."( Compatibility and stability of non-ionic iodinated contrast media in peritoneal dialysis solution and safe practice considerations for CT peritoneography.
Badugu, SK; Crabtree, JH; Gellens, ME; Kaushal, A; Mancini, A; Rappai, J, 2023
)
0.91
" However, little information was available about whether ICM-derived DBPs are toxic to aquatic organisms."( Disinfection byproducts of iopamidol, iohexol, diatrizoate and their distinct acute toxicity on Scenedesmus sp., Daphnia magna and Danio rerio.
Liu, H; Watson, P; Yang, F; Yang, X; Zhou, N, 2023
)
1.21

Pharmacokinetics

iopamidol 370 (a nonionic water organic iodine compound) during ivp in infants and children. The elimination half-life of iop amidol before hemodialysis was 69. Furthermore, the disappearance of iohexol from the brain parenchyma is approximately logarithmic.

ExcerptReferenceRelevance
"In normal healthy subjects radiographic contrast media are cleared by the kidneys with a half-life of approximately 2 h and a total body clearance of 8 l/h."( Clearance of iopamidol, a non-ionic contrast medium, by CAPD in patients with end-stage renal failure.
Burwell, N; Donnelly, PK; McBurney, A; Walls, J; Ward, JW; Watkin, EM, 1992
)
0.65
" The main pharmacokinetic parameters were calculated on the basis of bi-compartimental open model."( Pharmacokinetics of iopamidol in adults with renal failure.
Cambi, V; Cerutti, R; Corradi, A; Maccarini, P; Menta, R, 1990
)
0.6
"Four nonionic contrast media (iohexol, iopamidol, iopromide, and iosimide) are compared in this clinical study in their pharmacokinetic behavior with an ionic reference preparation (meglumine diatrizoate)."( Pharmacokinetics of iohexol, iopamidol, iopromide, and iosimide compared with meglumine diatrizoate.
Hartwig, P; Mützel, W; Taenzer, V, 1989
)
0.84
"This research was aimed at evaluating the pharmacokinetic parameters of iopamidol 370 (a nonionic water organic iodine compound) during ivp in infants and children."( Pharmacokinetics of iopamidol 370 in infants and children during ivp.
Beluffi, G; Cerutti, R; Fiori, P; Martini, A, 1989
)
0.83
"The elimination half-life of iopamidol before hemodialysis was 69."( Hemodialysis and iopamidol clearance after subclavian venography.
Burwell, N; Donnelly, PK; McBurney, A; Walls, J; Ward, JW; Watkin, EM, 1993
)
0.92
" For pharmacokinetic analysis, the determination of total iomeprol content was performed by a high-performance liquid chromatography assay procedure in blood, urine, and fecal samples collected before the dose and serially after the dose, up to 120 hours."( Safety and pharmacokinetics of a new liposomal liver-specific contrast agent for CT: results of clinical testing in nonpatient volunteers.
Alvino, S; Ceriati, S; Fouillet, X; Lorusso, V; Luzzani, F; Pianezzola, P; Rummeny, EJ; Spinazzi, A, 2000
)
0.31
" Its pharmacokinetic profile was compatible with nonspecific distribution into the extracellular fluid space and specific distribution into a deep compartment."( Safety and pharmacokinetics of a new liposomal liver-specific contrast agent for CT: results of clinical testing in nonpatient volunteers.
Alvino, S; Ceriati, S; Fouillet, X; Lorusso, V; Luzzani, F; Pianezzola, P; Rummeny, EJ; Spinazzi, A, 2000
)
0.31
" The elimination half-life increased progressively with increasing renal impairment."( Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis.
Alvino, S; Lorusso, V; Spinazzi, A; Taroni, P, 2001
)
0.31
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"We calculated the contrast medium aortic arrival time (TAR), the time to reach the trigger threshold (effective TAR), the slope of the linear equation of the enhancement unit (enhancement rate), and the time to peak aortic enhancement from the TECs of the pharmacokinetic analysis and retrospective clinical study."( Operation of bolus tracking system for prediction of aortic peak enhancement at multidetector row computed tomography: pharmacokinetic analysis and clinical study.
Hayashi, H; Ichikawa, K; Kidoya, E; Kimura, H; Suzuki, M; Yamaguchi, I, 2008
)
0.35
"In the pharmacokinetic analysis, the enhancement rate-simulated under conditions of injection duration 30 s and iodine load per body weight 500 mg/kg-was 27."( Operation of bolus tracking system for prediction of aortic peak enhancement at multidetector row computed tomography: pharmacokinetic analysis and clinical study.
Hayashi, H; Ichikawa, K; Kidoya, E; Kimura, H; Suzuki, M; Yamaguchi, I, 2008
)
0.35
" Current pharmacokinetic models have been based on invasive methods to measure drug concentrations, limiting them in spatial resolution, and restricting the research to larger rodents."( Cochlear pharmacokinetics - Micro-computed tomography and learning-prediction modeling for transport parameter determination.
Borkholder, DA; Budzevich, MM; Cahill, ND; Frisina, RD; Moudgalya, SS; Walton, JP; Wilson, K; Zhu, X, 2019
)
0.51
"To propose a pharmacokinetic non-linear analysis method to determine contrast medium (CM) dose for computed tomography (CT) hepatic enhancement to improve body size dependency and validate the proposed CM dose determination method through a clinical study."( Determination of contrast medium dose for hepatic CT enhancement with improved body size dependency using a non-linear analysis based on pharmacokinetic principles.
Bae, KT; Fang, Y; Hibino, T; Ichikawa, K; Ito, S; Kawashima, H, 2020
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
" The authors administered arterial infusion of 5-fluorouracil (5-FU) combined with concurrent radiation therapy to enhance the antitumor effect of chemotherapy."( Arterial infusion of 5-fluorouracil combined with concurrent radiotherapy for unresectable pancreatic cancer: results from a pilot study.
Anai, H; Kichikawa, K; Morimoto, K; Sakaguchi, H; Tamamoto, T; Tanaka, T; Yamamoto, K, 2007
)
0.34
"Arterial infusion of 5-FU combined with concurrent radiation therapy is tolerable and can produce a high response rate with encouraging survival duration for unresectable pancreatic cancer."( Arterial infusion of 5-fluorouracil combined with concurrent radiotherapy for unresectable pancreatic cancer: results from a pilot study.
Anai, H; Kichikawa, K; Morimoto, K; Sakaguchi, H; Tamamoto, T; Tanaka, T; Yamamoto, K, 2007
)
0.34
"The study aimed to prospectively evaluate the radiation dose reduction potential and image quality (IQ) of a high-concentration contrast media (HCCM) injection protocol in combination with a low tube current (mAs) in coronary computed tomography angiography."( Evaluation of a High Concentrated Contrast Media Injection Protocol in Combination with Low Tube Current for Dose Reduction in Coronary Computed Tomography Angiography: A Randomized, Two-center Prospective Study.
Hua, Y; Jin, X; Li, C; Mao, D; Shi, K; Sun, Y; Wang, M; Xu, J, 2017
)
0.46
"HCCM combined with low tube current allows dose reduction in coronary computed tomography angiography and does not compromise IQ."( Evaluation of a High Concentrated Contrast Media Injection Protocol in Combination with Low Tube Current for Dose Reduction in Coronary Computed Tomography Angiography: A Randomized, Two-center Prospective Study.
Hua, Y; Jin, X; Li, C; Mao, D; Shi, K; Sun, Y; Wang, M; Xu, J, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" This visualization is achieved by a differential gray-white matter enhancement, possibly due to a shielding effect of the white matter surrounding the gray matter, a difference in absorption rate between gray and white matter, or an increased rate of re-absorption of water-soluble contrast by the more highly vascularized deep gray matter."( The myeloneurogram.
Jinkins, JR, 1986
)
0.27
" This visualization is achieved by a poorly understood differential gray/white-matter enhancement, possibly due to either a shielding effect of the white matter as it envelops the gray matter, a differential absorption rate between gray and white matter, or a greater rate of reabsorption of contrast by the more highly vascularized gray matter."( The parenchymal CT myelogram: in vivo imaging of the gray matter of the spinal cord.
Al-Kawi, MZ; Bashir, R; Jinkins, JR; Siquiera, E,
)
0.13
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

CT imaging was continuously performed over 60 min, while an intravenous constant infusion with iopamidol 370 was started at a dosage of 1 ml/h. In patient studies, Isovue 300 (iopamidols) was injected at a dose of 1ml/kg patient body weight. Mean iopAmidol dosing was 1.

ExcerptRelevanceReference
" In patient studies, Isovue 300 (iopamidol) was injected at a dosage of 1 ml/kg patient body weight."( In vivo CT measurement of blood-brain transfer constant of iopamidol in human brain tumors.
Brown, T; Del Maestro, RF; Kozak, R; Lee, TY; Yeung, WT, 1992
)
0.81
" The drug dosage was worked out for adults as well as for children."( [Descending myelography with water-soluble contrast agents using methods of lateral puncture of the great occipital cistern].
Gasanov, IaK; Romanova, NV; Tissen, TP,
)
0.13
" Contrast media (cm) dosage varied from 150 to 300 ml (2."( [Selective coronarography and left ventriculography using iopamidol in the early phase of myocardial infarct].
Bellanti, G; Benenati, PM; Piscitelli, G; Ricci Maccarini, P,
)
0.38
" A dose-response curve for the release of glycosaminoglycan by chymopapain was linear when the amount of enzyme was plotted on a logarithmic scale against glycosaminoglycan release."( Effect of X-ray contrast media on the action of chymopapain on the intervertebral disc: an in vitro study of cartilage degradation.
Barrett, AJ; Buttle, DJ; Tudor, J, 1984
)
0.27
" The high osmolality of these media did not always permit a dosage sufficient for kidney imaging in the nephrographic and in the pyelographic phase."( [Significance of a nonionic renographic contrast medium (Iopamidol 300) in the roentgen diagnosis of the kidneys and urinary tract in children].
Fendel, H; Schneider, K, 1984
)
0.51
" The contrast medium was injected rapidly into an antecubital vein within 2-3 min in most cases, using a standard dosage of 1 ml kg-1 body weight."( Iomeprol versus iopromide for intravenous urography.
de Geeter, P; Melchior, H, 1994
)
0.29
" Intravenous daily dosing for 4 weeks showed that iomeprol was well tolerated at doses as high as the maximum dose anticipated for clinical use."( Toxicological safety assessment of iomeprol, a new X-ray contrast agent.
de Haën, C; Luzzani, F; Morisetti, A; Tirone, P, 1994
)
0.29
"To assess the optimal contrast dosage for brain enhanced CT."( [Optimal dosage of contrast material in brain enhanced CT].
Kominami, M; Kusano, S; Tamura, T; Tsushima, Y; Yokoyama, H, 1999
)
0.3
" Awareness of wide interindividual transfer variation and steady intraindividual transfer may help to specify dosage and effect expectation of intrathecal drug therapy."( Conditions of iodine contrast transfer from lumbosacral CSF to blood.
Koch, HC; Kunzmann, V; Seyfert, S, 2003
)
0.32
" CT imaging was continuously performed over 60 min, while an intravenous constant infusion with iopamidol 370 was started at a dosage of 1 ml/h."( High-resolution imaging of murine myocardial infarction with delayed-enhancement cine micro-CT.
Badea, C; Figueiredo, JL; Hedlund, LW; Johnson, GA; Nahrendorf, M; Sosnovik, DE; Weissleder, R, 2007
)
0.56
" Limits in contrast dosing may negatively impact the evaluation of patients undergoing cardiac catheterization for myocardial infarction and acute coronary syndrome."( Risk of nephropathy is not increased by the administration of larger volume of contrast during coronary angiography.
Anderson, JL; Bair, TL; Horne, BD; Lappé, DL; Madsen, TE; Muhlestein, JB; Pearson, RR, 2009
)
0.35
"Although airway gene transfer research in mouse models relies on bolus fluid dosing into the nose or trachea, the dynamics and immediate fate of delivered gene transfer agents are poorly understood."( Synchrotron phase-contrast X-ray imaging reveals fluid dosing dynamics for gene transfer into mouse airways.
Donnelley, M; Jamison, RA; Parsons, DW; Siu, KK, 2012
)
0.38
" This makes it potentially feasible to automatically individualize CM dosage by CT."( Automatic individualized contrast medium dosage during hepatic computed tomography by using computed tomography dose index volume (CTDI(vol)).
Aspelin, P; Björk, J; Brismar, TB; Cederlund, K; Nyman, U; Svensson, A, 2014
)
0.4
"To compare a fixed-dose intravenous iodinated contrast medium protocol with weight-based dosing protocols for abdominal computed tomography (CT)."( Comparison between a fixed-dose contrast protocol and a weight-based contrast dosing protocol in abdominal CT.
George, AJ; Hamilton, MC; Manghat, NE, 2016
)
0.43
"Fifty patients were scanned using a fixed-dose protocol, 50 patients were scanned using a full-dose weight-based contrast dosing protocol, and 13 patients were scanned using a reduced dose weight-based protocol."( Comparison between a fixed-dose contrast protocol and a weight-based contrast dosing protocol in abdominal CT.
George, AJ; Hamilton, MC; Manghat, NE, 2016
)
0.43
" Using a full-dose weight-based contrast dosing protocol, there was no longer a statistically significant correlation or trend implying a more consistent degree of enhancement over a spectrum of patient weights."( Comparison between a fixed-dose contrast protocol and a weight-based contrast dosing protocol in abdominal CT.
George, AJ; Hamilton, MC; Manghat, NE, 2016
)
0.43
"Weight-based contrast medium dosing has been shown to objectively provide more consistent vessel and solid-organ enhancement and subjectively improve image quality across a spectrum of weights."( Comparison between a fixed-dose contrast protocol and a weight-based contrast dosing protocol in abdominal CT.
George, AJ; Hamilton, MC; Manghat, NE, 2016
)
0.43
"The modified liver CT protocol employed a faster injection rate (5 vs 3 mL/s), later arterial phase (20-second vs 10-second postbolus trigger), and weight-based dosing of iodinated contrast (1."( Assessment of Cirrhotic Liver Enhancement With Multiphasic Computed Tomography Using a Faster Injection Rate, Late Arterial Phase, and Weight-Based Contrast Dosing.
Costa, AF; Eddy, K, 2017
)
0.46
"A liver CT protocol with later arterial phase, faster injection rate, and weight-based dosing of intravenous contrast significantly improves liver enhancement and iodine concentrations in patients with cirrhosis, resulting in significantly fewer suboptimal studies."( Assessment of Cirrhotic Liver Enhancement With Multiphasic Computed Tomography Using a Faster Injection Rate, Late Arterial Phase, and Weight-Based Contrast Dosing.
Costa, AF; Eddy, K, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
radioopaque mediumA substance having the property of absorbing, and therefore being opaque to, electromagnetic radiation, particularly X-rays.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
benzenedicarboxamide
organoiodine compoundAn organoiodine compound is a compound containing at least one carbon-iodine bond.
pentolA polyol with five hydroxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency11.89600.006038.004119,952.5996AID1159521; AID1159523
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID504865
AR proteinHomo sapiens (human)Potency8.53740.000221.22318,912.5098AID743040; AID743042; AID743054
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency7.58960.000214.376460.0339AID720691; AID720692; AID720719
estrogen nuclear receptor alphaHomo sapiens (human)Potency7.77550.000229.305416,493.5996AID743069; AID743080; AID743091
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency7.16690.001723.839378.1014AID743083
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency7.07950.10009.191631.6228AID1346983
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.10950.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency1.41250.891312.067628.1838AID1487
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (83)

Assay IDTitleYearJournalArticle
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,548)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990474 (18.60)18.7374
1990's552 (21.66)18.2507
2000's515 (20.21)29.6817
2010's926 (36.34)24.3611
2020's81 (3.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 68.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index68.06 (24.57)
Research Supply Index8.12 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index121.69 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (68.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials448 (15.44%)5.53%
Reviews55 (1.90%)6.00%
Case Studies270 (9.31%)4.05%
Observational8 (0.28%)0.25%
Other2,120 (73.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]